News
Infex begins study of pseudomonas aeruginosa candidate RESP-X
Infex – a company focusing on anti-infectives specialist – has announced that the first patients have been dosed in its phase 1 study researching candidate RESP-X.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
Infex – a company focusing on anti-infectives specialist – has announced that the first patients have been dosed in its phase 1 study researching candidate RESP-X.